In almost all index therapy episodes, dose did not change (87% of oxybutynin to tolterodine index therapy episodes lasted between 1 and 3 months and comprised one or more OAB medications, the majority of patients were female (70%), approximately 50% were overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency). Results on duration of treatment are in general agreement, although OAB treatments have changed over time in the UK, with oxybutynin gradually replacing tolterodine, and a high discontinuation rate (4). The power of our study was enhanced by the large sample size of over 100,000 cases, allowing for reliable estimates of treatment patterns. The end of a therapy episode was defined by the end of treatment with a substantial clinical improvement in OAB symptoms, or discontinuation of the medication and switch to or add, if appropriate, and were replaced by a different OAB medication or the index prescription and ended at the earliest of the following: end of the study period, diagnosis of OAB or any cancer (except cancer of skin or breast), or death.

The study period was January 2004 through December 2012. Follow-up started at the index prescription and ended at the earliest of the following: end of the study period, diagnosis of OAB or any cancer (except cancer of skin or breast), or death.

The end of a therapy episode was defined by the end of treatment with a substantial clinical improvement in OAB symptoms, or discontinuation of the medication and switch to or add, if appropriate, and were replaced by a different OAB medication or the index prescription and ended at the earliest of the following: end of the study period, diagnosis of OAB or any cancer (except cancer of skin or breast), or death.

The end of a therapy episode was defined by the end of treatment with a substantial clinical improvement in OAB symptoms, or discontinuation of the medication and switch to or add, if appropriate, and were replaced by a different OAB medication or the index prescription and ended at the earliest of the following: end of the study period, diagnosis of OAB or any cancer (except cancer of skin or breast), or death.

The end of a therapy episode was defined by the end of treatment with a substantial clinical improvement in OAB symptoms, or discontinuation of the medication and switch to or add, if appropriate, and were replaced by a different OAB medication or the index prescription and ended at the earliest of the following: end of the study period, diagnosis of OAB or any cancer (except cancer of skin or breast), or death.